{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:24:45Z","timestamp":1785558285467,"version":"3.56.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-024-00687-5","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T02:02:29Z","timestamp":1730167349000},"page":"7-31","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effect of nebivolol monotherapy or combination therapy on blood pressure levels in patients with hypertension: an updated systematic review and multilevel meta-analysis of 91 randomized controlled trials"],"prefix":"10.1007","volume":"32","author":[{"given":"Athanasios","family":"Manolis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paschalis","family":"Karakasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Patoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalis","family":"Doumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolis","family":"Kallistratos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costas","family":"Thomopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Koutsaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"687_CR1","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/J.JACC.2023.11.007","volume":"82","author":"GA Mensah","year":"2023","unstructured":"Mensah GA, Fuster V, Murray CJL, et al. Global burden of cardiovascular diseases and risks, 1990\u20132022. J Am Coll Cardiol. 2023;82:2350\u2013473. https:\/\/doi.org\/10.1016\/J.JACC.2023.11.007.","journal-title":"J Am Coll Cardiol"},{"key":"687_CR2","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480.","journal-title":"J Hypertens"},{"key":"687_CR3","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertens. 2020;75:1334\u201357. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15026.","journal-title":"Hypertens"},{"key":"687_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/01.MJT.0000149923.39085.44","volume":"13","author":"TJ Cleophas","year":"2006","unstructured":"Cleophas TJ, Agrawal R, Lichtenthal A, M\u00e4kel W, Fici F. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients. Am J Ther. 2006;13:192\u20137. https:\/\/doi.org\/10.1097\/01.MJT.0000149923.39085.44.","journal-title":"Am J Ther"},{"key":"687_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2165\/1120274-000000000-00000","volume":"9","author":"CM Baldwin","year":"2009","unstructured":"Baldwin CM, Keam SJ. Nebivolol: in the treatment of hypertension in the US. Am J Cardiovasc Drugs. 2009;9:253\u201360. https:\/\/doi.org\/10.2165\/1120274-000000000-00000.","journal-title":"Am J Cardiovasc Drugs"},{"key":"687_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/11530710-000000000-00000","volume":"70","author":"O Kamp","year":"2010","unstructured":"Kamp O, Metra M, Bugatti S, et al. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Drugs. 2010;70:41\u201356. https:\/\/doi.org\/10.2165\/11530710-000000000-00000.","journal-title":"Drugs"},{"key":"687_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1023\/a:1026180325278","volume":"17","author":"I Czuriga","year":"2003","unstructured":"Czuriga I, Riecansky I, Bodnar J, et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther. 2003;17:257\u201363. https:\/\/doi.org\/10.1023\/a:1026180325278.","journal-title":"Cardiovasc Drugs Ther"},{"key":"687_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/08038020310000104","volume":"1","author":"EA Rosei","year":"2003","unstructured":"Rosei EA, Rizzoni D, Comini S, Boari G. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press Suppl. 2003;1:30\u20135. https:\/\/doi.org\/10.1080\/08038020310000104.","journal-title":"Blood Press Suppl"},{"key":"687_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1573402119666230330082128","volume":"19","author":"SM Hanna","year":"2023","unstructured":"Hanna SM, Rabea HM, Abdelrahim MEA, Mahmoud HB. Effect of fixed-dose combination amlodipine\/valsartan in comparison to two drug combination nebivolol\/valsartan on 24-hour ambulatory blood pressure. Curr Hypertens Rev. 2023;19:123\u20139. https:\/\/doi.org\/10.2174\/1573402119666230330082128.","journal-title":"Curr Hypertens Rev"},{"key":"687_CR10","doi-asserted-by":"publisher","first-page":"6159883","DOI":"10.1155\/2022\/6159883","volume":"2022","author":"R Pawlak-Chomicka","year":"2022","unstructured":"Pawlak-Chomicka R, Krauze T, Uruski P, et al. The effect of antihypertensive drugs on NADH in newly diagnosed primary hypertension. Cardiol Res Pract. 2022;2022:6159883. https:\/\/doi.org\/10.1155\/2022\/6159883.","journal-title":"Cardiol Res Pract"},{"key":"687_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s43044-022-00254-0","volume":"74","author":"E-ZM Sultan","year":"2022","unstructured":"Sultan E-ZM, Rabea H, Elberry AA, Mahmoud HB. Effect of Amlodipine\/Nebivolol combination therapy on central BP and PWV compared to Amlodipine\/Valsartan combination therapy. Egypt Hear J Off Bull Egypt Soc Cardiol. 2022;74:15. https:\/\/doi.org\/10.1186\/s43044-022-00254-0.","journal-title":"Egypt Hear J Off Bull Egypt Soc Cardiol"},{"key":"687_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejim.2022.06.013","volume":"103","author":"G Gungor","year":"2022","unstructured":"Gungor G, Perk H, Soyupek S, Baykal B, Demir M, Sezer MT. Nebivolol protects erectile functions compared to Metoprolol in hypertensive men with atherogenic, venogenic, psychogenic erectile dysfunction: a prospective, randomized, cross-over, clinical trial. Eur J Intern Med. 2022;103:69\u201375. https:\/\/doi.org\/10.1016\/j.ejim.2022.06.013.","journal-title":"Eur J Intern Med"},{"key":"687_CR13","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions| Cochrane Training n.d. https:\/\/training.cochrane.org\/handbook\/current (accessed January 17, 2023)."},{"key":"687_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/BMJ.N71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372. https:\/\/doi.org\/10.1136\/BMJ.N71.","journal-title":"BMJ"},{"key":"687_CR15","doi-asserted-by":"publisher","unstructured":"Haddaway NR, Grainger MJ, Gray CT. citationchaser: An R package and Shiny app for forward and backward citations chasing in academic searching 2021. https:\/\/doi.org\/10.5281\/ZENODO.4543513.","DOI":"10.5281\/ZENODO.4543513"},{"key":"687_CR16","doi-asserted-by":"publisher","unstructured":"Wallace BC, Small K, Brodley CE, Lau J, Trikalinos TA. Deploying an interactive machine learning system in an Evidence-based Practice Center: Abstrackr. IHI\u201912 - Proc 2nd ACM SIGHIT Int Heal Informatics Symp 2012. pp. 819\u201323. https:\/\/doi.org\/10.1145\/2110363.2110464.","DOI":"10.1145\/2110363.2110464"},{"key":"687_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.L4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/BMJ.L4898.","journal-title":"BMJ"},{"key":"687_CR18","unstructured":"Chapter 6: Choosing effect measures and computing estimates of effect| Cochrane Training n.d. https:\/\/training.cochrane.org\/handbook\/archive\/v6.1\/chapter-06?fbclid=IwAR3Bf9gpJhBm02jDyB5I0v-75MMFczJXjPLDZ8D70s3KZKr8AM8hWBElMcE#section-6-5-2-8 (accessed December 14, 2023)."},{"key":"687_CR19","unstructured":"GRADEpro n.d. https:\/\/www.gradepro.org\/ (accessed March 1, 2023)."},{"key":"687_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/sj.jhh.1000550","volume":"11","author":"L Van Nueten","year":"1997","unstructured":"Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1997;11:813\u20139. https:\/\/doi.org\/10.1038\/sj.jhh.1000550.","journal-title":"J Hum Hypertens"},{"key":"687_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00045391-199807000-00006","volume":"5","author":"L Van Nueten","year":"1998","unstructured":"Van Nueten L, Lacourci\u00e8re Y, Vyssoulis G, et al. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther. 1998;5:237\u201343. https:\/\/doi.org\/10.1097\/00045391-199807000-00006.","journal-title":"Am J Ther"},{"key":"687_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/sj.jhh.1000571","volume":"12","author":"L Van Nueten","year":"1998","unstructured":"Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1998;12:135\u201340. https:\/\/doi.org\/10.1038\/sj.jhh.1000571.","journal-title":"J Hum Hypertens"},{"key":"687_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/17843286.1999.11754204","volume":"54","author":"L Van Nueten","year":"1999","unstructured":"Van Nueten L, Rish\u00f8j Nielsen M, Vertommen C, Dupont AG, Robertson JI. Nebivolol versus enalapril in essential hypertension: a long-term double-blind comparative trial. Acta Clin Belg. 1999;54:19\u201325. https:\/\/doi.org\/10.1080\/17843286.1999.11754204.","journal-title":"Acta Clin Belg"},{"key":"687_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/080370502760050421","volume":"11","author":"A Mazza","year":"2002","unstructured":"Mazza A, Gil-Extremera B, Maldonato A, Toutouzas T, Pessina AC. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press. 2002;11:182\u20138. https:\/\/doi.org\/10.1080\/080370502760050421.","journal-title":"Blood Press"},{"key":"687_CR25","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1161\/01.HYP.0000070956.57418.22","volume":"41","author":"L Ghiadoni","year":"2003","unstructured":"Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertens. 2003;41:1281\u20136. https:\/\/doi.org\/10.1161\/01.HYP.0000070956.57418.22.","journal-title":"Hypertens"},{"key":"687_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/107424840300800206","volume":"8","author":"E Rizos","year":"2003","unstructured":"Rizos E, Bairaktari E, Kostoula A, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther. 2003;8:127\u201334. https:\/\/doi.org\/10.1177\/107424840300800206.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"687_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/s1388-9842(03)00054-0","volume":"5","author":"S Nodari","year":"2003","unstructured":"Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail. 2003;5:621\u20137. https:\/\/doi.org\/10.1016\/s1388-9842(03)00054-0.","journal-title":"Eur J Heart Fail"},{"key":"687_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/08038020310023271","volume":"2","author":"G Grassi","year":"2003","unstructured":"Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl. 2003;2:35\u201340.","journal-title":"Blood Press Suppl"},{"key":"687_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215\u201325. https:\/\/doi.org\/10.1093\/eurheartj\/ehi115.","journal-title":"Eur Heart J"},{"key":"687_CR30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/01.hjh.0000160216.86597.ff","volume":"23","author":"A Fratta Pasini","year":"2005","unstructured":"Fratta Pasini A, Garbin U, Nava MC, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens. 2005;23:589\u201396. https:\/\/doi.org\/10.1097\/01.hjh.0000160216.86597.ff.","journal-title":"J Hypertens"},{"key":"687_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.amjhyper.2004.08.039","volume":"18","author":"K Fountoulaki","year":"2005","unstructured":"Fountoulaki K, Dimopoulos V, Giannakoulis J, Zintzaras E, Triposkiadis F. Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan. Am J Hypertens. 2005;18:171\u20137. https:\/\/doi.org\/10.1016\/j.amjhyper.2004.08.039.","journal-title":"Am J Hypertens"},{"key":"687_CR32","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.amjhyper.2005.03.733","volume":"18","author":"LM Van Bortel","year":"2005","unstructured":"Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens. 2005;18:1060\u20136. https:\/\/doi.org\/10.1016\/j.amjhyper.2005.03.733.","journal-title":"Am J Hypertens"},{"key":"687_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2165\/00044011-200525060-00006","volume":"25","author":"B Boydak","year":"2005","unstructured":"Boydak B, Nalbantgil S, Fici F, et al. A randomised comparison of the effects of nebivolol and atenolol with and without chlorthalidone on the sexual function of hypertensive men. Clin Drug Investig. 2005;25:409\u201316. https:\/\/doi.org\/10.2165\/00044011-200525060-00006.","journal-title":"Clin Drug Investig"},{"key":"687_CR34","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1097\/01.hjh.0000234121.48272.67","volume":"24","author":"T Kaiser","year":"2006","unstructured":"Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens. 2006;24:1397\u2013403. https:\/\/doi.org\/10.1097\/01.hjh.0000234121.48272.67.","journal-title":"J Hypertens"},{"key":"687_CR35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ijcard.2006.03.046","volume":"116","author":"T Celik","year":"2007","unstructured":"Celik T, Yuksel UC, Iyisoy A, et al. Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol. Int J Cardiol. 2007;116:206\u201311. https:\/\/doi.org\/10.1016\/j.ijcard.2006.03.046.","journal-title":"Int J Cardiol"},{"key":"687_CR36","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/j.1524-6175.2007.06679.x","volume":"9","author":"RJ Weiss","year":"2007","unstructured":"Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich). 2007;9:667\u201376. https:\/\/doi.org\/10.1111\/j.1524-6175.2007.06679.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"687_CR37","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1524-6175.2007.07548.x","volume":"9","author":"E Saunders","year":"2007","unstructured":"Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007;9:866\u201375. https:\/\/doi.org\/10.1111\/j.1524-6175.2007.07548.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"687_CR38","first-page":"383","volume":"7","author":"A O\u011fuz","year":"2007","unstructured":"O\u011fuz A, Uzunlulu M, Yorulmaz E, Yal\u00e7in Y, Hekim N, Fici F. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus. Anadolu Kardiyol Derg. 2007;7:383\u20137.","journal-title":"Anadolu Kardiyol Derg"},{"key":"687_CR39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ajh.2008.156","volume":"21","author":"A Mahmud","year":"2008","unstructured":"Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens. 2008;21:663\u20137. https:\/\/doi.org\/10.1038\/ajh.2008.156.","journal-title":"Am J Hypertens"},{"key":"687_CR40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s12325-008-0065-3","volume":"25","author":"M Tuncer","year":"2008","unstructured":"Tuncer M, Guntekin U, Gunes Y, Gumrukcuoglu HA, Eryonucu B. Differential effects of nebivolol and atenolol on transmitral diastolic filling parameters in patients with essential hypertension. Adv Ther. 2008;25:619\u201326. https:\/\/doi.org\/10.1007\/s12325-008-0065-3.","journal-title":"Adv Ther"},{"key":"687_CR41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/10623320802125565","volume":"15","author":"H Korkmaz","year":"2008","unstructured":"Korkmaz H, Karaca I, Ko\u00e7 M, Onalan O, Yilmaz M, Bilen MN. Early effects of treatment with nebivolol and quinapril on endothelial function in patients with hypertension. Endothelium. 2008;15:149\u201355. https:\/\/doi.org\/10.1080\/10623320802125565.","journal-title":"Endothelium"},{"key":"687_CR42","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s12325-008-0087-x","volume":"25","author":"MB Yilmaz","year":"2008","unstructured":"Yilmaz MB, Erdem A, Yalta K, Turgut OO, Yilmaz A, Tandogan I. Impact of beta-blockers on sleep in patients with mild hypertension: a randomized trial between nebivolol and metoprolol. Adv Ther. 2008;25:871\u201383. https:\/\/doi.org\/10.1007\/s12325-008-0087-x.","journal-title":"Adv Ther"},{"key":"687_CR43","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/ajh.2008.260","volume":"21","author":"AF Pasini","year":"2008","unstructured":"Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens. 2008;21:1251\u20137. https:\/\/doi.org\/10.1038\/ajh.2008.260.","journal-title":"Am J Hypertens"},{"key":"687_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.amjcard.2008.08.063","volume":"103","author":"V Papademetriou","year":"2009","unstructured":"Papademetriou V. Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension. Am J Cardiol. 2009;103:273\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2008.08.063.","journal-title":"Am J Cardiol"},{"key":"687_CR45","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.clinthera.2009.08.028","volume":"31","author":"FW Germino","year":"2009","unstructured":"Germino FW. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients. Clin Ther. 2009;31:1946\u201356. https:\/\/doi.org\/10.1016\/j.clinthera.2009.08.028.","journal-title":"Clin Ther"},{"key":"687_CR46","first-page":"45","volume":"14","author":"II Simova","year":"2009","unstructured":"Simova II, Todorova-Konstantinova RR, Denchev SV. Effects of nebivolol versus bisoprolol on endothelial function in hypertensive patients. Exp Clin Cardiol. 2009;14:45\u20139.","journal-title":"Exp Clin Cardiol"},{"key":"687_CR47","doi-asserted-by":"publisher","first-page":"E20","DOI":"10.1002\/clc.20508","volume":"33","author":"M Greathouse","year":"2010","unstructured":"Greathouse M. Nebivolol efficacy and safety in patients with stage I-II hypertension. Clin Cardiol. 2010;33:E20\u20137. https:\/\/doi.org\/10.1002\/clc.20508.","journal-title":"Clin Cardiol"},{"key":"687_CR48","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1185\/03007995.2010.497326","volume":"26","author":"J Heitmann","year":"2010","unstructured":"Heitmann J, Greulich T, Reinke C, et al. Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnoea activity in patients with essential hypertension and OSA. Curr Med Res Opin. 2010;26:1925\u201332. https:\/\/doi.org\/10.1185\/03007995.2010.497326.","journal-title":"Curr Med Res Opin"},{"key":"687_CR49","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/1753944710387629","volume":"4","author":"H Punzi","year":"2010","unstructured":"Punzi H, Lewin A, Luki\u0107 T, Goodin T, Chen W. Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial. Ther Adv Cardiovasc Dis. 2010;4:349\u201357. https:\/\/doi.org\/10.1177\/1753944710387629.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"687_CR50","doi-asserted-by":"publisher","first-page":"401","DOI":"10.4103\/0253-7613.71918","volume":"42","author":"GN Sahana","year":"2010","unstructured":"Sahana GN, Sarala N, Kumar TN, Lakshmaiah V. A comparative study of nebivolol and (S) atenolol on blood pressure and heart rate on essential hypertensive patients. Indian J Pharmacol. 2010;42:401\u20135. https:\/\/doi.org\/10.4103\/0253-7613.71918.","journal-title":"Indian J Pharmacol"},{"key":"687_CR51","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jash.2010.11.003","volume":"5","author":"R Kandavar","year":"2011","unstructured":"Kandavar R, Higashi Y, Chen W, et al. The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension. J Am Soc Hypertens. 2011;5:161\u20135. https:\/\/doi.org\/10.1016\/j.jash.2010.11.003.","journal-title":"J Am Soc Hypertens"},{"key":"687_CR52","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1097\/HJH.0b013e3283442f37","volume":"29","author":"D Vinereanu","year":"2011","unstructured":"Vinereanu D, Gherghinescu C, Ciobanu AO, et al. Reversal of subclinical left ventricular dysfunction by antihypertensive treatment: a prospective trial of nebivolol against metoprolol. J Hypertens. 2011;29:809\u201317. https:\/\/doi.org\/10.1097\/HJH.0b013e3283442f37.","journal-title":"J Hypertens"},{"key":"687_CR53","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1161\/HYPERTENSIONAHA.110.155507","volume":"57","author":"P Kampus","year":"2011","unstructured":"Kampus P, Serg M, Kals J, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertens. 2011;57:1122\u20138. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.155507.","journal-title":"Hypertens"},{"key":"687_CR54","doi-asserted-by":"publisher","first-page":"310","DOI":"10.5152\/akd.2011.081","volume":"11","author":"O Erdo\u011fan","year":"2011","unstructured":"Erdo\u011fan O, Ertem B, Altun A. Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial. Anadolu Kardiyol Derg. 2011;11:310\u20133. https:\/\/doi.org\/10.5152\/akd.2011.081.","journal-title":"Anadolu Kardiyol Derg"},{"key":"687_CR55","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1097\/HJH.0b013e3283471151","volume":"29","author":"C Diehm","year":"2011","unstructured":"Diehm C, Pittrow D, Lawall H. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens. 2011;29:1448\u201356. https:\/\/doi.org\/10.1097\/HJH.0b013e3283471151.","journal-title":"J Hypertens"},{"key":"687_CR56","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1161\/HYPERTENSIONAHA.110.169169","volume":"58","author":"C Espinola-Klein","year":"2011","unstructured":"Espinola-Klein C, Weisser G, Jagodzinski A, et al. \u03b2-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertens. 2011;58:148\u201354. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.169169.","journal-title":"Hypertens"},{"key":"687_CR57","doi-asserted-by":"publisher","first-page":"437","DOI":"10.4103\/0253-7613.83117","volume":"43","author":"VA Badar","year":"2011","unstructured":"Badar VA, Hiware SK, Shrivastava MP, Thawani VR, Hardas MM. Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. Indian J Pharmacol. 2011;43:437\u201340. https:\/\/doi.org\/10.4103\/0253-7613.83117.","journal-title":"Indian J Pharmacol"},{"key":"687_CR58","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cardfail.2011.05.001","volume":"17","author":"G Marazzi","year":"2011","unstructured":"Marazzi G, Volterrani M, Caminiti G, et al. Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients. J Card Fail. 2011;17:703\u20139. https:\/\/doi.org\/10.1016\/j.cardfail.2011.05.001.","journal-title":"J Card Fail"},{"key":"687_CR59","doi-asserted-by":"publisher","first-page":"563","DOI":"10.5543\/tkda.2011.01585","volume":"39","author":"B Altun","year":"2011","unstructured":"Altun B, Acar G, Ak\u00e7ay A, S\u00f6kmen A, Kaya H, K\u00f6ro\u011flu S. Comparative effects of nebivolol and valsartan on atrial electromechanical coupling in newly diagnosed stage 1 hypertensive patients. Turk Kardiyol Dern Ars. 2011;39:563\u20137. https:\/\/doi.org\/10.5543\/tkda.2011.01585.","journal-title":"Turk Kardiyol Dern Ars"},{"key":"687_CR60","first-page":"1359","volume":"15","author":"N Ca\u011flar","year":"2011","unstructured":"Ca\u011flar N, Dincer I. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial. Eur Rev Med Pharmacol Sci. 2011;15:1359\u201368.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"687_CR61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ijcard.2011.10.099","volume":"155","author":"C Vitale","year":"2012","unstructured":"Vitale C, Marazzi G, Iellamo F, et al. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. Int J Cardiol. 2012;155:279\u201384. https:\/\/doi.org\/10.1016\/j.ijcard.2011.10.099.","journal-title":"Int J Cardiol"},{"key":"687_CR62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/eurjhf\/hfr161","volume":"14","author":"VM Conraads","year":"2012","unstructured":"Conraads VM, Metra M, Kamp O, et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail. 2012;14:219\u201325. https:\/\/doi.org\/10.1093\/eurjhf\/hfr161.","journal-title":"Eur J Heart Fail"},{"key":"687_CR63","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1161\/HYPERTENSIONAHA.111.189589","volume":"59","author":"K Ayers","year":"2012","unstructured":"Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertens. 2012;59:893\u20138. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.189589.","journal-title":"Hypertens"},{"key":"687_CR64","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jash.2012.02.002","volume":"6","author":"A Lewin","year":"2012","unstructured":"Lewin A, Lasseter KC, Dong F, Whalen JC. Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial. J Am Soc Hypertens. 2012;6:228\u201336. https:\/\/doi.org\/10.1016\/j.jash.2012.02.002.","journal-title":"J Am Soc Hypertens"},{"key":"687_CR65","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1161\/HYPERTENSIONAHA.111.189381","volume":"59","author":"AJ Stears","year":"2012","unstructured":"Stears AJ, Woods SH, Watts MM, et al. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertens. 2012;59:934\u201342. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.189381.","journal-title":"Hypertens"},{"key":"687_CR66","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.mehy.2012.05.011","volume":"79","author":"A Parlak","year":"2012","unstructured":"Parlak A, Iyisoy A, Aydogan U, Cakir E, Saglam K. The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients. Med Hypotheses. 2012;79:294\u20138. https:\/\/doi.org\/10.1016\/j.mehy.2012.05.011.","journal-title":"Med Hypotheses"},{"key":"687_CR67","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1742-7843.2012.00911.x","volume":"111","author":"RJ Zepeda","year":"2012","unstructured":"Zepeda RJ, Castillo R, Rodrigo R, et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic Clin Pharmacol Toxicol. 2012;111:309\u201316. https:\/\/doi.org\/10.1111\/j.1742-7843.2012.00911.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"687_CR68","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3109\/00365513.2012.691991","volume":"72","author":"M Serg","year":"2012","unstructured":"Serg M, Kampus P, Kals J, et al. Nebivolol and metoprolol: long-term effects on inflammation and oxidative stress in essential hypertension. Scand J Clin Lab Invest. 2012;72:427\u201332. https:\/\/doi.org\/10.3109\/00365513.2012.691991.","journal-title":"Scand J Clin Lab Invest"},{"key":"687_CR69","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1751-7176.2012.00666.x","volume":"14","author":"MA Weber","year":"2012","unstructured":"Weber MA, Basile J, Stapff M, Khan B, Zhou D. Blood pressure effects of combined \u03b2-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril. J Clin Hypertens (Greenwich). 2012;14:588\u201392. https:\/\/doi.org\/10.1111\/j.1751-7176.2012.00666.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"687_CR70","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/0167-5273(92)90238-x","volume":"35","author":"TY Chan","year":"1992","unstructured":"Chan TY, Woo KS, Nicholls MG. The application of nebivolol in essential hypertension: a double-blind, randomized, placebo-controlled study. Int J Cardiol. 1992;35:387\u201395. https:\/\/doi.org\/10.1016\/0167-5273(92)90238-x.","journal-title":"Int J Cardiol"},{"key":"687_CR71","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00059-012-3695-9","volume":"38","author":"MR Sayin","year":"2013","unstructured":"Sayin MR, Aydin M, Dogan SM, Karabag T, Cetiner MA, Aktop Z. Aortic elastic properties: effects of carvedilol versus nebivolol. Herz. 2013;38:299\u2013305. https:\/\/doi.org\/10.1007\/s00059-012-3695-9.","journal-title":"Herz"},{"key":"687_CR72","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.clinthera.2012.12.015","volume":"35","author":"A Lewin","year":"2013","unstructured":"Lewin A, Punzi H, Luo X, Stapff M. Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial. Clin Ther. 2013;35:142\u201352. https:\/\/doi.org\/10.1016\/j.clinthera.2012.12.015.","journal-title":"Clin Ther"},{"key":"687_CR73","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40256-013-0010-y","volume":"13","author":"RJ Weiss","year":"2013","unstructured":"Weiss RJ, Stapff M, Lin Y. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial. Am J Cardiovasc Drugs Drugs Devices Other Interv. 2013;13:129\u201340. https:\/\/doi.org\/10.1007\/s40256-013-0010-y.","journal-title":"Am J Cardiovasc Drugs Drugs Devices Other Interv"},{"key":"687_CR74","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/jch.12071","volume":"15","author":"P Deedwania","year":"2013","unstructured":"Deedwania P, Shea J, Chen W, Brener L. Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes. J Clin Hypertens (Greenwich). 2013;15:270\u20138. https:\/\/doi.org\/10.1111\/jch.12071.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"687_CR75","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/jch.12118","volume":"15","author":"A Briasoulis","year":"2013","unstructured":"Briasoulis A, Oliva R, Kalaitzidis R, et al. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich). 2013;15:473\u20139. https:\/\/doi.org\/10.1111\/jch.12118.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"687_CR76","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/FJC.0b013e31829f716a","volume":"62","author":"F Fici","year":"2013","unstructured":"Fici F, Celik T, Balta S, et al. Comparative effects of nebivolol and metoprolol on red cell distribution width and neutrophil\/lymphocyte ratio in patients with newly diagnosed essential hypertension. J Cardiovasc Pharmacol. 2013;62:388\u201393. https:\/\/doi.org\/10.1097\/FJC.0b013e31829f716a.","journal-title":"J Cardiovasc Pharmacol"},{"key":"687_CR77","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jch.12169","volume":"15","author":"TD Giles","year":"2013","unstructured":"Giles TD, Khan BV, Lato J, Brener L, Ma Y, Lukic T. Nebivolol monotherapy in younger adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial. J Clin Hypertens (Greenwich). 2013;15:687\u201393. https:\/\/doi.org\/10.1111\/jch.12169.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"687_CR78","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/jch.12210","volume":"15","author":"P Studinger","year":"2013","unstructured":"Studinger P, Tab\u00e1k \u00c1G, Chen C-H, Salvi P, Othmane TEH, Torzsa P, et al. The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial. J Clin Hypertens (Greenwich). 2013;15:910\u20137. https:\/\/doi.org\/10.1111\/jch.12210.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"687_CR79","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1097\/HJH.0b013e328364fbca","volume":"31","author":"DW Eeftinck Schattenkerk","year":"2013","unstructured":"Eeftinck Schattenkerk DW, van den Bogaard B, Cammenga M, Westerhof BE, Stroes ESG, van den Born B-JH. Lack of difference between nebivolol\/hydrochlorothiazide and metoprolol\/hydrochlorothiazide on aortic wave augmentation and central blood pressure. J Hypertens. 2013;31:2447\u201354. https:\/\/doi.org\/10.1097\/HJH.0b013e328364fbca.","journal-title":"J Hypertens"},{"key":"687_CR80","doi-asserted-by":"publisher","first-page":"608683","DOI":"10.1155\/2013\/608683","volume":"2013","author":"HU Yazici","year":"2013","unstructured":"Yazici HU, Ozduman H, Aydar Y, Birdane A. Effects of metoprolol and nebivolol on exercise blood pressure in patients with mild hypertension. ScientificWorldJournal. 2013;2013:608683. https:\/\/doi.org\/10.1155\/2013\/608683.","journal-title":"ScientificWorldJournal"},{"key":"687_CR81","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/j.1552-4604.1992.tb05778.x","volume":"32","author":"Y Lacourci\u00e8re","year":"1992","unstructured":"Lacourci\u00e8re Y, Poirier L, Lefebvre J, Provencher P, Arnott W. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol. 1992;32:660\u20136. https:\/\/doi.org\/10.1002\/j.1552-4604.1992.tb05778.x.","journal-title":"J Clin Pharmacol"},{"key":"687_CR82","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jash.2013.09.001","volume":"8","author":"C Koumaras","year":"2014","unstructured":"Koumaras C, Tziomalos K, Stavrinou E, et al. Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens. 2014;8:74\u201382. https:\/\/doi.org\/10.1016\/j.jash.2013.09.001.","journal-title":"J Am Soc Hypertens"},{"key":"687_CR83","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1161\/HYPERTENSIONAHA.114.03476","volume":"64","author":"RA Preston","year":"2014","unstructured":"Preston RA, Afshartous D, Materson BJ, Rodco R, Alonso AB. Effects of nebivolol versus metoprolol on sodium sensitivity and renal sodium handling in hypertensive Hispanic postmenopausal women. Hypertens. 2014;64:287\u201395. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.03476.","journal-title":"Hypertens"},{"key":"687_CR84","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/S0140-6736(14)60614-0","volume":"383","author":"TD Giles","year":"2014","unstructured":"Giles TD, Weber MA, Basile J, et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet (London, England). 2014;383:1889\u201398. https:\/\/doi.org\/10.1016\/S0140-6736(14)60614-0.","journal-title":"Lancet (London, England)"},{"key":"687_CR85","doi-asserted-by":"publisher","first-page":"HC01","DOI":"10.7860\/JCDR\/2014\/7728.4419","volume":"8","author":"VV Bhosale","year":"2014","unstructured":"Bhosale VV, Inamdar SC, Karande VB, Burute SR, Murthy MB, Ghatak A. Beneficial effects of nebivolol in comparison with atenolol on safety and tolerability in essential hypertension. J Clin Diagn Res. 2014;8:HC01-4. https:\/\/doi.org\/10.7860\/JCDR\/2014\/7728.4419.","journal-title":"J Clin Diagn Res"},{"key":"687_CR86","doi-asserted-by":"publisher","first-page":"485","DOI":"10.4103\/0253-7613.140577","volume":"46","author":"RS Patel","year":"2014","unstructured":"Patel RS, Sharma KH, Kamath NA, Patel NH, Thakkar AM. Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: a pharmacoeconomic comparison of antihypertensive efficacy of beta blockers. Indian J Pharmacol. 2014;46:485\u20139. https:\/\/doi.org\/10.4103\/0253-7613.140577.","journal-title":"Indian J Pharmacol"},{"key":"687_CR87","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jash.2014.12.013","volume":"9","author":"SS Hayek","year":"2015","unstructured":"Hayek SS, Poole JC, Neuman R, Morris AA, et al. Differential effects of nebivolol and metoprolol on arterial stiffness, circulating progenitor cells, and oxidative stress. J Am Soc Hypertens. 2015;9:206\u201313. https:\/\/doi.org\/10.1016\/j.jash.2014.12.013.","journal-title":"J Am Soc Hypertens"},{"key":"687_CR88","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jash.2015.08.003","volume":"9","author":"TD Giles","year":"2015","unstructured":"Giles TD, Bakris G, Oparil S, et al. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. J Am Soc Hypertens. 2015;9:845\u201354. https:\/\/doi.org\/10.1016\/j.jash.2015.08.003.","journal-title":"J Am Soc Hypertens"},{"key":"687_CR89","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/jch.12745","volume":"18","author":"AHJ Santos","year":"2016","unstructured":"Santos AHJ, Casey MJ, Bucci CM, Rehman S, Segal MS. Nebivolol effects on nitric oxide levels, blood pressure, and renal function in kidney transplant patients. J Clin Hypertens (Greenwich). 2016;18:741\u20139. https:\/\/doi.org\/10.1111\/jch.12745.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"687_CR90","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1161\/HYPERTENSIONAHA.115.06979","volume":"67","author":"KJ Diehl","year":"2016","unstructured":"Diehl KJ, Stauffer BL, Dow CA, et al. Chronic nebivolol treatment suppresses endothelin-1-mediated vasoconstrictor tone in adults with elevated blood pressure. Hypertens. 2016;67:1196\u2013204. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.115.06979.","journal-title":"Hypertens"},{"key":"687_CR91","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1152\/ajpheart.00237.2016","volume":"311","author":"A Velasco","year":"2016","unstructured":"Velasco A, Solow E, Price A, et al. Differential effects of nebivolol vs. metoprolol on microvascular function in hypertensive humans. Am J Physiol Heart Circ Physiol. 2016;311:118\u201324. https:\/\/doi.org\/10.1152\/ajpheart.00237.2016.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"687_CR92","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3109\/10641969309041625","volume":"15","author":"G Simon","year":"1993","unstructured":"Simon G, Johnson ML. Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension. Clin Exp Hypertens. 1993;15:501\u20139. https:\/\/doi.org\/10.3109\/10641969309041625.","journal-title":"Clin Exp Hypertens"},{"key":"687_CR93","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/1074248416644987","volume":"22","author":"AG Ozy\u0131ld\u0131z","year":"2017","unstructured":"Ozy\u0131ld\u0131z AG, Eroglu S, Bal U, Atar I, Okyay K, Muderrisoglu H. Effects of carvedilol compared to nebivolol on insulin resistance and lipid profile in patients with essential hypertension. J Cardiovasc Pharmacol Ther. 2017;22:65\u201370. https:\/\/doi.org\/10.1177\/1074248416644987.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"687_CR94","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s12325-016-0427-1","volume":"33","author":"G Grassi","year":"2017","unstructured":"Grassi G, Seravalle G, Brambilla G, et al. Multicenter randomized double-blind comparison of nebivolol plus HCTZ and Irbesartan plus HCTZ in the treatment of isolated systolic hypertension in elderly patients: results of the NEHIS study. Adv Ther. 2017;33:2173\u201387. https:\/\/doi.org\/10.1007\/s12325-016-0427-1.","journal-title":"Adv Ther"},{"key":"687_CR95","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/jch.12965","volume":"19","author":"CW Mende","year":"2017","unstructured":"Mende CW, Giles TD, Bharucha DB, Ferguson WG, Mallick M, Patel MD. Efficacy of nebivolol-valsartan single-pill combination in obese and nonobese patients with hypertension. J Clin Hypertens (Greenwich). 2017;19:632\u20139. https:\/\/doi.org\/10.1111\/jch.12965.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"687_CR96","doi-asserted-by":"publisher","first-page":"7643628","DOI":"10.1155\/2017\/7643628","volume":"2017","author":"M Hussain","year":"2017","unstructured":"Hussain M, Saeed M, Babar MZM, Atif MA, Akhtar L. Nebivolol attenuates neutrophil lymphocyte ratio: a marker of subclinical inflammation in hypertensive patients. Int J Hypertens. 2017;2017:7643628. https:\/\/doi.org\/10.1155\/2017\/7643628.","journal-title":"Int J Hypertens"},{"key":"687_CR97","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007437","author":"BL Stauffer","year":"2017","unstructured":"Stauffer BL, Dow CA, Diehl KJ, Bammert TD, Greiner JJ, DeSouza CA. Nebivolol, but not metoprolol, treatment improves endothelial fibrinolytic capacity in adults with elevated blood pressure. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/JAHA.117.007437.","journal-title":"J Am Heart Assoc"},{"key":"687_CR98","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41371-017-0019-9","volume":"32","author":"DA Duprez","year":"2017","unstructured":"Duprez DA, Florea N, Duval S, Koukol C, Cohn JN. Effect of nebivolol or atenolol versus placebo on cardiovascular health in subjects with borderline blood pressure: the EVIDENCE study. J Hum Hypertens. 2017;32:20\u20135. https:\/\/doi.org\/10.1038\/s41371-017-0019-9.","journal-title":"J Hum Hypertens"},{"key":"687_CR99","doi-asserted-by":"publisher","first-page":"e11717","DOI":"10.1097\/MD.0000000000011717","volume":"97","author":"M Walczak-Ga\u0142\u0119zewska","year":"2018","unstructured":"Walczak-Ga\u0142\u0119zewska M, Szuli\u0144ska M, Miller-Kasprzak E, Pupek-Musialik D, Bogda\u0144ski P. The effect of nebivolol and ramipril on selected biochemical parameters, arterial stiffness, and circadian profile of blood pressure in young men with primary hypertension: a 12-week prospective randomized, open-label study trial. Medicine (Baltimore). 2018;97:e11717. https:\/\/doi.org\/10.1097\/MD.0000000000011717.","journal-title":"Medicine (Baltimore)"},{"key":"687_CR100","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40292-018-0286-8","volume":"25","author":"SM Farag","year":"2018","unstructured":"Farag SM, Rabea HM, Mahmoud HB. Effect of amlodipine\/valsartan versus nebivolol\/valsartan fixed dose combinations on peripheral and central blood pressure. High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens. 2018;25:407\u201313. https:\/\/doi.org\/10.1007\/s40292-018-0286-8.","journal-title":"High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens"},{"key":"687_CR101","doi-asserted-by":"publisher","first-page":"e0239039","DOI":"10.1371\/journal.pone.0239039","volume":"15","author":"H Kook","year":"2020","unstructured":"Kook H, Hong SJ, Yang K-S, Lee S, Kim J-S, Park CG. Comparison of nebivolol versus diltiazem in improving coronary artery spasm and quality of life in patients with hypertension and vasospastic angina: a prospective, randomized, double-blind pilot study. PLoS ONE. 2020;15:e0239039. https:\/\/doi.org\/10.1371\/journal.pone.0239039.","journal-title":"PLoS ONE"},{"key":"687_CR102","first-page":"1891","volume":"34","author":"A Majid","year":"2021","unstructured":"Majid A, Javed A, Hussain M, Faisal Z, Elahi A, Akhtar L. Effect of nebivolol beneficial on lipid profile and glycemic control in comparison with Atenolol in patients with type 2 DM with concomitant hypertension. Pak J Pharm Sci. 2021;34:1891\u20135.","journal-title":"Pak J Pharm Sci"},{"key":"687_CR103","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/00045391-199406000-00012","volume":"1","author":"Y Lacourci\u00e8re","year":"1994","unstructured":"Lacourci\u00e8re Y, Lefebvre J, Poirier L, Archambault F, Arnott W. A double-blind crossover comparison of nebivolol and lisinopril in the treatment of ambulatory hypertension. Am J Ther. 1994;1:74\u201380. https:\/\/doi.org\/10.1097\/00045391-199406000-00012.","journal-title":"Am J Ther"},{"key":"687_CR104","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/jhh.2009.33","volume":"24","author":"JM Neutel","year":"2010","unstructured":"Neutel JM, Smith DHG, Gradman AH. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension. J Hum Hypertens. 2010;24:64\u201373. https:\/\/doi.org\/10.1038\/jhh.2009.33.","journal-title":"J Hum Hypertens"},{"key":"687_CR105","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jama.2013.184182","volume":"310","author":"CK Chow","year":"2013","unstructured":"Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959\u201368. https:\/\/doi.org\/10.1001\/jama.2013.184182.","journal-title":"JAMA"},{"key":"687_CR106","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/HJH.0b013e328342ca97","volume":"29","author":"G Corrao","year":"2011","unstructured":"Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29:610\u20138. https:\/\/doi.org\/10.1097\/HJH.0b013e328342ca97.","journal-title":"J Hypertens"},{"key":"687_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.11.028","author":"AJ Manolis","year":"2023","unstructured":"Manolis AJ, Kallistratos MS, Koutsaki M, Doumas M, Poulimenos LE, Parissis J, et al. The diagnostic approach and management of hypertension in the emergency department. Eur J Intern Med. 2023. https:\/\/doi.org\/10.1016\/j.ejim.2023.11.028.","journal-title":"Eur J Intern Med"},{"key":"687_CR108","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","volume":"55","author":"AK Gupta","year":"2010","unstructured":"Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertens. 2010;55:399\u2013407. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.139816.","journal-title":"Hypertens"},{"key":"687_CR109","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40885-021-00165-3","volume":"27","author":"KI Cho","year":"2021","unstructured":"Cho KI, Jeon DW, Ahn HS, et al. Efficacy and safety of nebivolol in Korean patients with hypertension by age and sex: a subanalysis from the BENEFIT-KOREA study. Clin Hypertens. 2021;27:9. https:\/\/doi.org\/10.1186\/s40885-021-00165-3.","journal-title":"Clin Hypertens"},{"key":"687_CR110","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/HJH.0000000000002296","volume":"38","author":"J Shin","year":"2020","unstructured":"Shin J, Choi YJ, Hong G-R, et al. Real-world efficacy and safety of nebivolol in Korean patients with hypertension from the BENEFIT KOREA study. J Hypertens. 2020;38:527\u201335. https:\/\/doi.org\/10.1097\/HJH.0000000000002296.","journal-title":"J Hypertens"},{"key":"687_CR111","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2217\/fca.14.51","volume":"10","author":"MS Kallistratos","year":"2014","unstructured":"Kallistratos MS, Poulimenos LE, Manolis AJ. Vasodilator \u03b2-blockers: a different class of antihypertensive agents? Fut Cardiol. 2014;10:669\u201371. https:\/\/doi.org\/10.2217\/fca.14.51.","journal-title":"Fut Cardiol"},{"key":"687_CR112","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1756287216685027","volume":"9","author":"RP Sharp","year":"2017","unstructured":"Sharp RP, Gales BJ. Nebivolol versus other beta blockers in patients with hypertension and erectile dysfunction. Ther Adv Urol. 2017;9:59\u201363. https:\/\/doi.org\/10.1177\/1756287216685027.","journal-title":"Ther Adv Urol"},{"key":"687_CR113","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000076677","volume":"71","author":"M Cazzola","year":"2004","unstructured":"Cazzola M, Matera MG, Ruggeri P, et al. Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD. Respiration. 2004;71:159\u201364. https:\/\/doi.org\/10.1159\/000076677.","journal-title":"Respiration"},{"key":"687_CR114","first-page":"749","volume":"14","author":"LM Van Bortel","year":"2010","unstructured":"Van Bortel LM. Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: a post-marketing surveillance study. Eur Rev Med Pharmacol Sci. 2010;14:749\u201358.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"687_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.009","volume":"81","author":"A Manolis","year":"2020","unstructured":"Manolis A, Doumas M, Ferri C, Mancia G. Erectile dysfunction and adherence to antihypertensive therapy: focus on \u03b2-blockers. Eur J Intern Med. 2020;81:1\u20136. https:\/\/doi.org\/10.1016\/j.ejim.2020.07.009.","journal-title":"Eur J Intern Med"},{"key":"687_CR116","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1097\/HJH.0b013e32830dd0c6","volume":"26","author":"A Manolis","year":"2008","unstructured":"Manolis A, Doumas M. Sexual dysfunction: the \u201cprima ballerina\u201d of hypertension-related quality-of-life complications. J Hypertens. 2008;26:2074\u201384. https:\/\/doi.org\/10.1097\/HJH.0b013e32830dd0c6.","journal-title":"J Hypertens"},{"key":"687_CR117","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/HJH.0000000000002284","volume":"38","author":"JS Del Mauro","year":"2020","unstructured":"Del Mauro JS, Prince PD, Allo MA, Santander Plantamura Y, Morett\u00f3n MA, Gonz\u00e1lez GE, et al. Effects of third-generation \u03b2-blockers, atenolol or amlodipine on blood pressure variability and target organ damage in spontaneously hypertensive rats. J Hypertens. 2020;38:536\u201345. https:\/\/doi.org\/10.1097\/HJH.0000000000002284.","journal-title":"J Hypertens"},{"key":"687_CR118","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jphs.2015.09.002","volume":"129","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Vanhoutte PM, Leung SWS. Vascular nitric oxide: beyond eNOS. J Pharmacol Sci. 2015;129:83\u201394. https:\/\/doi.org\/10.1016\/j.jphs.2015.09.002.","journal-title":"J Pharmacol Sci"},{"key":"687_CR119","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cjca.2015.02.008","volume":"31","author":"AC Montezano","year":"2015","unstructured":"Montezano AC, Dulak-Lis M, Tsiropoulou S, Harvey A, Briones AM, Touyz RM. Oxidative stress and human hypertension: vascular mechanisms, biomarkers, and novel therapies. Can J Cardiol. 2015;31:631\u201341. https:\/\/doi.org\/10.1016\/j.cjca.2015.02.008.","journal-title":"Can J Cardiol"},{"key":"687_CR120","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2174\/157016112799959323","volume":"10","author":"M Wehland","year":"2012","unstructured":"Wehland M, Grosse J, Simonsen U, Infanger M, Bauer J, Grimm D. The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease. Curr Vasc Pharmacol. 2012;10:378\u201390. https:\/\/doi.org\/10.2174\/157016112799959323.","journal-title":"Curr Vasc Pharmacol"},{"key":"687_CR121","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/HJH.0000000000000024","volume":"32","author":"M Bordicchia","year":"2014","unstructured":"Bordicchia M, Pocognoli A, D\u2019Anzeo M, et al. Nebivolol induces, via \u03b23 adrenergic receptor, lipolysis, uncoupling protein 1, and reduction of lipid droplet size in human adipocytes. J Hypertens. 2014;32:389\u201396. https:\/\/doi.org\/10.1097\/HJH.0000000000000024.","journal-title":"J Hypertens"},{"key":"687_CR122","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1097\/HJH.0000000000002523","volume":"38","author":"C Thomopoulos","year":"2020","unstructured":"Thomopoulos C, Bazoukis G, Tsioufis C, Mancia G. Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. J Hypertens. 2020;38:1669\u201381. https:\/\/doi.org\/10.1097\/HJH.0000000000002523.","journal-title":"J Hypertens"},{"key":"687_CR123","doi-asserted-by":"publisher","first-page":"300060520931625","DOI":"10.1177\/0300060520931625","volume":"48","author":"J-Y Liu","year":"2020","unstructured":"Liu J-Y, Guo L-N, Peng W-Z, et al. Efficacy and safety of nebivolol in hypertensive patients: a meta-analysis of randomized controlled trials. J Int Med Res. 2020;48:300060520931625. https:\/\/doi.org\/10.1177\/0300060520931625.","journal-title":"J Int Med Res"},{"key":"687_CR124","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40256-020-00422-0","volume":"21","author":"VB Seleme","year":"2021","unstructured":"Seleme VB, Marques GL, Mendes AEM, Rotta I, Pereira M, J\u00fanior EL, et al. Nebivolol for the treatment of essential systemic arterial hypertension: a systematic review and meta-analysis. Am J Cardiovasc Drugs Drugs Devices Other Interv. 2021;21:165\u201380. https:\/\/doi.org\/10.1007\/s40256-020-00422-0.","journal-title":"Am J Cardiovasc Drugs Drugs Devices Other Interv"},{"key":"687_CR125","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2021.03.035","volume":"88","author":"S Paolillo","year":"2021","unstructured":"Paolillo S, Dell\u2019Aversana S, Esposito I, Poccia A, Perrone FP. The use of \u03b2-blockers in patients with heart failure and comorbidities: doubts, certainties and unsolved issues. Eur J Intern Med. 2021;88:9\u201314. https:\/\/doi.org\/10.1016\/j.ejim.2021.03.035.","journal-title":"Eur J Intern Med"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-024-00687-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-024-00687-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-024-00687-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T10:04:36Z","timestamp":1738231476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-024-00687-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":125,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1007\/s40292-024-00687-5","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"29 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Athanasios Manolis: Conceptualization, Methodology, Investigation, Project administration, Writing\u2014review & editing. Paschalis Karakasis: Conceptualization, Methodology, Investigation, Formal analysis, Data curation, Visualization, Writing -original draft, Writing\u2014review & editing. Dimitrios Patoulias: Conceptualization, Methodology, Investigation, Writing\u2014original draft, Writing\u2014review & editing. Michalis Doumas: Conceptualization, Methodology, Investigation, Project administration, Writing\u2014review & editing. Manolis Kallistratos: Conceptualization, Methodology, Investigation, Writing\u2014review & editing. Costas Thomopoulos: Conceptualization, Methodology, Investigation, Writing\u2014review & editing. Maria Koutsaki: Investigation, Writing\u2014review & editing. Guido Grassi: Conceptualization, Methodology, Investigation, Project administration, Writing\u2014review & editing. Giuseppe Mancia: Conceptualization, Methodology, Investigation, Project administration, Writing\u2014review & editing. All authors read and approved the final manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contribution"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors for its design or conduction.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was prepared a priori and registered in OSF ().","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Protocol"}},{"value":"The data generated in this research will be shared on reasonable request to the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}